A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
收藏DataCite Commons2025-12-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012221/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
提供机构：
Vivli
创建时间：
2025-12-16
